Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
Along with nucleic acids, proteins, and lipids, carbohydrates stand as one of four main components of cellular architecture. However, glycobiology (or carbohydrate bioscience) is little understood by non-experts, partly because carbohydrates are a complex, diverse class of molecules structurally and functionally. In recent years, advances in computational analytics (glycomics) have allowed us to better interpret and realize the importance of glycobiology in human health and disease, and glycans and their associated processes have been shown to play a significant role across a variety of disease types. As the biomedical sciences continue to adopt multi-omic and precision medicine approaches, a greater understanding of glycobiology is essential for maintaining healthy physiology and advancing disease treatment.
Translational Glycobiology in Human Health and Disease offers a deep examination of glycobiology for experts and non-experts alike in areas ranging from the role of glycobiology in chronic and infectious diseases to advances in technologies for higher throughput analysis and diagnosis. While keeping human health in the forefront, this book integrates a thorough discussion of glycobiology fundamentals with its growing areas of application and societal impact. With emphasis throughout on the interdisciplinary nature of glycosciences, this book also features perspectives from the health, computational (glycoanalytics), materials, biopharmaceutical, and diagnostic sciences.
Disease and speciality areas addressed include gycoimmunology, neuroglycobiology, commensal glycobiology, gut health, regenerative medicine and glycobiology, glycobiology and cancer, congenital disorders of glycosylation, infectious disease glycobiology, and parasite glycobiology. Computational approaches discussed, supporting the advance of new research, include advanced glycoanalytics, glycomics microarrays, glycoengineering, and glycol systems biology. Additionally, authors consider impact areas for society and public health, such as glycobiology and entrepreneurship, policy and regulatory requirements for glycosylation, future research, and translation to new diagnostics and drug discovery.
- Provides a deep, foundational overview of glycoscience and its translational potential, highlighting glycobiology’s growing role in human health and disease study
- Examines a broad range of relevant disease areas and applications of glycobiology in policy and public health
- Features chapter contributions from leading, international experts in the field, fully integrating perspectives from the health, computational, materials, biopharmaceutical, and diagnostic sciencess
Active researchers in biochemistry, molecular biology, nutrition, and cell biology; industrial scientists; biomedical engineers; nutritional scientists; pharmacologists; clinician scientists; medicinal chemists; analytical chemists
Section 1: Glycobiology
2. Carbohydrates and human glycosylation
3. Carbohydrate-binding proteins
4. Carbohydrate-active enzymes
Section 2: Glycobiology and health
7. Commensal glycobiology and gut health
8. Microbiota accessible carbohydrates and the gut microbiome
9. Regenerative medicine and glycobiology
10. Exosome glycosylation for signalling and function
Section 3: Glycobiology and disease
12. Altered glycosylation in autoimmune diseases
13. Metabolic diseases: Disorders of carbohydrate metabolism and lysosomal storage
14. Congenital Disorders of Glycosylation
15. Microbial infectious disease glycobiology
16. Parasite glycobiology
17. Glycobiology of neurodegenerative diseases
18. Glycobiology of neural injury and regeneration
Section 4: Glycotechnologies
19. Diagnostics and novel carbohydrate recognition molecules
20. Advanced glycoanalytics
21. Glycomics microarrays
22. Glycoengineering and systems biology
23. Computational Glycobiology
24. Carbohydrate-incorporated Biomaterials
Section 5: Glycobiology and Society
25. Translational glycobiology and entrepreneurship for health
26. Glycobiology: Public engagement and society
27. Policy and regulatory requirements for glycosylation
28. Public health and translational glycobiology
29. Future perspectives/ summary
- No. of pages:
- © Academic Press 2021
- 1st November 2020
- Academic Press
- Paperback ISBN:
Dr. Michelle Kilcoyne is Lecturer in Glycosciences at the National University of Ireland Galway. Dr. Michelle Kilcoyne completed her PhD in analytical carbohydrate chemistry in the School of Chemistry at NUI Galway in 2004, specialising in structural analysis of bacterial polysaccharides. She then took up a postdoctoral position in Arizona State University where she further specialised in mass spectrometry and HPLC, as well as expanding her interests to mammalian glycosylation. She returned as a postdoctoral researcher to NUI Galway in 2007 working on industry-supported and European projects, developing high throughput platforms for carbohydrate profiling. In 2014 Dr. Kilcoyne was appointed Lecturer in Glycosciences, is currently a member of Discipline of Microbiology at NUI Galway and leads the Carbohydrate Signalling Group. She is the recipient of a Royal Society of Chemistry Analytical Chemistry Trust Fund Fellowship for 2018. Her main interests are in glycoanalytics, novel glycomics platform development and carbohydrate-mediated host-microbe interactions.
Lecturer in Glycosciences, National University of Ireland, Galway, Ireland
Prof. Lokesh Joshi is Director of the Advanced Glycoscience Research Cluster and leader of the Glycoscience Group at NUI Galway, a Co-Director of CÚRAM, a medical device centre, and the Vice-President for Research at NUI Galway. His principal focus of research is in understanding the roles of glycans and lectins in health and diseases and developing novel technologies for glycomics. Prof. Joshi has been involved in two spin out companies, Arizona Engineered Therapeutics (AzERx) and Aquila Biosciences. The NIH and VC sources funded AzERx to develop peptide-based therapeutics for vascular applications and AzERx was acquired by Orthologic (Now Capstone Therapeutics) in 2006. Aquila Bioscience is a healthcare company working on various projects funded by EI, EU, European Defence Agency and private industries. Prof. Joshi is an SFI-Stokes Professor of Glycosciences and the Irish representative on European Universities Association’s Research Programme Working group.
Director, Advanced Glycoscience Research Cluster and Leader, Glycoscience Group, NUI Galway, Ireland
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.